Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research
Rapid Dose Therapeutics (RDTCF) has provided an update on its collaboration with the University of Regina's Faculty of Kinesiology & Health Studies for an NFL-funded medical cannabis research project. The study focuses on examining cannabinoids' effects on sport concussion and pain management.
The project has entered the clinical trial phase, investigating the bioavailability of CBD through RDT's QuickStrip™ sublingual delivery system compared to standard oral formulation. The randomized, two-arm clinical study, approved by Health Canada, involves researchers from the Universities of Regina, Saskatchewan, and British Columbia.
The study specifically examines the pharmacokinetic parameters of non-psychoactive cannabidiol (CBD) and its metabolites in healthy young adults. The QuickStrip™ technology consists of rectangular oral thin films infused with cannabis extract that dissolve under the tongue, releasing the compound directly into the mucus membranes.
Rapid Dose Therapeutics (RDTCF) ha fornito un aggiornamento sulla sua collaborazione con la Facoltà di Kinesiologia e Studi sulla Salute dell'Università di Regina per un progetto di ricerca sul cannabis medico finanziato dalla NFL. Lo studio si concentra sull'esaminare gli effetti dei cannabinoidi sulle commozioni cerebrali sportive e sulla gestione del dolore.
Il progetto è entrato nella fase di sperimentazione clinica, indagando la biodisponibilità del CBD attraverso il sistema di somministrazione sublinguale QuickStrip™ di RDT, rispetto alla formulazione orale standard. Lo studio clinico randomizzato, approvato da Health Canada, coinvolge ricercatori delle Università di Regina, Saskatchewan e Columbia Britannica.
Lo studio esamina specificamente i parametri farmacocinetici del cannabidiolo (CBD) non psicoattivo e dei suoi metaboliti in giovani adulti sani. La tecnologia QuickStrip™ consiste in film sottili orali rettangolari infusi con estratto di cannabis che si sciolgono sotto la lingua, rilasciando il composto direttamente nelle membrane mucose.
Rapid Dose Therapeutics (RDTCF) ha proporcionado una actualización sobre su colaboración con la Facultad de Kinesiología y Estudios de Salud de la Universidad de Regina para un proyecto de investigación sobre cannabis médico financiado por la NFL. El estudio se centra en examinar los efectos de los cannabinoides en las conmociones cerebrales deportivas y en el manejo del dolor.
El proyecto ha entrado en la fase de ensayo clínico, investigando la biodisponibilidad del CBD a través del sistema de entrega sublingual QuickStrip™ de RDT en comparación con la formulación oral estándar. El estudio clínico aleatorizado, aprobado por Health Canada, involucra a investigadores de las Universidades de Regina, Saskatchewan y Columbia Británica.
El estudio examina específicamente los parámetros farmacocinéticos del cannabidiol (CBD) no psicoactivo y sus metabolitos en jóvenes adultos sanos. La tecnología QuickStrip™ consiste en películas orales delgadas rectangulares impregnadas con extracto de cannabis que se disuelven bajo la lengua, liberando el compuesto directamente en las membranas mucosas.
Rapid Dose Therapeutics (RDTCF)는 NFL 자금 지원을 받는 의료용 대마초 연구 프로젝트에 대해 레지나 대학교 운동학 및 건강 연구 학부와의 협력에 대한 업데이트를 제공했습니다. 이 연구는 스포츠 뇌진탕 및 통증 관리에 대한 카나비노이드의 영향을 조사하는 데 중점을 두고 있습니다.
이 프로젝트는 임상 시험 단계에 들어갔으며, RDT의 QuickStrip™ 설하 전달 시스템을 표준 경구 제형과 비교하여 CBD의 생체이용률을 조사하고 있습니다. 캐나다 보건부의 승인을 받은 이 무작위 이중 팔 임상 연구에는 레지나 대학교, 서스캐처원 대학교 및 브리티시컬럼비아 대학교의 연구자들이 참여하고 있습니다.
이 연구는 건강한 젊은 성인에서 비정신활성 카나비디올(CBD) 및 그 대사산물의 약리학적 매개변수를 구체적으로 조사합니다. QuickStrip™ 기술은 대마 추출물이 주입된 직사각형 경구용 얇은 필름으로, 혀 아래에서 용해되어 화합물을 점막으로 직접 방출합니다.
Rapid Dose Therapeutics (RDTCF) a fourni une mise à jour sur sa collaboration avec la Faculté de kinésiologie et d'études de la santé de l'Université de Regina pour un projet de recherche sur le cannabis médical financé par la NFL. L'étude se concentre sur l'examen des effets des cannabinoïdes sur les commotions sportives et la gestion de la douleur.
Le projet est entré dans la phase d'essai clinique, investiguant la biodisponibilité du CBD à travers le système de délivrance sublingual QuickStrip™ de RDT par rapport à la formulation orale standard. L'étude clinique randomisée, approuvée par Santé Canada, implique des chercheurs des Universités de Regina, de la Saskatchewan et de la Colombie-Britannique.
L'étude examine spécifiquement les paramètres pharmacocinétiques du cannabidiol (CBD) non psychoactif et de ses métabolites chez des jeunes adultes en bonne santé. La technologie QuickStrip™ consiste en des films oraux minces rectangulaires infusés d'extrait de cannabis qui se dissolvent sous la langue, libérant le composé directement dans les membranes muqueuses.
Rapid Dose Therapeutics (RDTCF) hat ein Update zu seiner Zusammenarbeit mit der Fakultät für Kinesiologie und Gesundheitsstudien der University of Regina für ein von der NFL finanziertes medizinisches Cannabisforschungsprojekt bereitgestellt. Die Studie konzentriert sich auf die Untersuchung der Auswirkungen von Cannabinoiden auf Sportkonkussionen und Schmerzmanagement.
Das Projekt ist in die klinische Prüfungsphase eingetreten und untersucht die Bioverfügbarkeit von CBD durch das sublinguale Abgabesystem QuickStrip™ von RDT im Vergleich zu herkömmlichen oralen Formulierungen. Die randomisierte, zweigleisige klinische Studie, die von Health Canada genehmigt wurde, umfasst Forscher von den Universitäten Regina, Saskatchewan und British Columbia.
Die Studie untersucht speziell die pharmakokinetischen Parameter von nicht psychoaktivem Cannabidiol (CBD) und seinen Metaboliten bei gesunden jungen Erwachsenen. Die QuickStrip™-Technologie besteht aus rechteckigen oralen Dünnfilmen, die mit Cannabisextrakt infundiert sind und unter der Zunge aufgelöst werden, wodurch die Verbindung direkt in die Schleimhäute freigesetzt wird.
- Health Canada approval obtained for the clinical trial
- Partnership with major research institutions strengthens scientific credibility
- NFL funding supports the research program
- Study could validate QuickStrip™ delivery system's efficacy
- Clinical trial still in early stages with no results yet
- No immediate revenue impact from the research program
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech Company providing proprietary oral delivery platform via sublingual thin film strip technology, is proud to announce an update to the ongoing collaboration project with the Faculty of Kinesiology & Health Studies at the University of Regina on their National Football League (NFL) - funded medical cannabis research project to examine the effects of cannabinoids on sport concussion and pain management.
The NFL program, titled "Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports" is led by Dr. J. Patrick Neary, exercise physiologist and professor in the Faculty of Kinesiology and Health Studies at the University of Regina.
As announced on May 29, 2024, RDT is participating in a randomized, two-arm clinical study, approved by Health Canada, which is part of the broader clinical program designed by a multidisciplinary team of cerebrovascular and neuro-physiologists, clinical psychologists, pharmacokineticists, and physicians from the Universities of Regina, Saskatchewan, and British Columbia (Kelowna).
The primary research objective of the study is to determine the relative oral bioavailability and other pharmacokinetic (PK) parameters of the non-psychoactive cannabidiol (CBD) and its metabolites, when administered to a healthy young adult population using RDT's sublingual QuickStrip™ product, versus a standard oral (ingestible powder) formulation. The strips are rectangular oral thin films infused with cannabis extract, which, when placed under the tongue, dissolve and release the cannabis extract into the mucus membranes of the mouth. The project has moved into the critical clinical trial stage designed and now being implemented to provide the necessary analytical data to differentiate the impact of mucosal delivery to the blood steam with a traditional oral dosage protocol utilizing CBD as the active ingredient in the study.
"Rapid Dose Therapeutics have helped us navigate the Health Canada regulatory process and is providing precisely dosed CBD strips for our pharmacokinetic study," Dr. Neary stated. "This clinical trail, a part of the overall NFL funded research program, is being conducted with our research group at the University of Saskatchewan under the leadership of Dr. Jane Alcorn to investigate the bioavailability of CBD strips in comparison to an oral dose of CBD. This study will help us determine how the body interacts with a substance for the duration that it is in the body, for the two different methods of CBD ingestion, i.e., oral ingestion vs. strips. CBD is known to be neuroprotective (protects the brain), and anti-inflammatory. The results of this study will be exceedingly important from a therapeutical perspective and has the potential to change not only the lives of current and former NFL players, but also the lives of anyone who may suffer from a concussion," Dr. Neary suggested.
"We are excited to partner with the University of Regina on this study," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "This collaboration reinforces RDT's commitment to advancing the science of cannabinoids and their potential applications. The data generated from this study will help determine the efficacy of the QuickStrip™ and serve as the basis for subsequent clinical studies where RDT's QuickStrip™ can be included."
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.
For more information about the Company, visit www.rapid-dose.com.
Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
investorrelations@rapid-dose.com
416-477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the Common Shared States. The securities described in this news release have not been and will not be registered under the Common Shared States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the Common Shared States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247766
FAQ
What is the primary objective of RDTCF's NFL-funded clinical trial?
How does RDTCF's QuickStrip™ technology deliver CBD in the clinical trial?
Which universities are involved in RDTCF's NFL cannabis research project?
What potential benefits does RDTCF's CBD study aim to demonstrate?
